David Greene, MD, MBA, Founder and CEOHowever, certain hurdles continue to keep regenerative therapies from attaining the status quo they deserve. There are still many facets of regenerative medicine that are yet to explore and address. As such, there is a lot of speculation, criticism, fallacy, debate, and, more importantly, optimism around regenerative therapies.
R3 Stem Cell has been at the forefront of performing regenerative therapies for the past decade. With over 16,000 regenerative therapies worldwide, they have never experienced a single significant adverse event. This is indeed a crowning achievement when compared to conventional treatment practices such as surgery and narcotic prescriptions.
“For years, we asked patients if they’d undergo regenerative therapy again or if they’d recommend it to friends and family. On average, 85 percent of our patients say yes. These are people with life-challenging conditions such as arthritis, diabetes or kidney failure, and multiple sclerosis,” prides David Greene, Founder and CEO, R3 Stem Cell. While specifying the types of stem cell treatments that R3 Stem Cell delivers, Greene mentions that they do not offer embryonic stem cell therapies that are obtained from aborted fetuses. The company primarily uses stem cells from donated umbilical cords and amniotic fluid, which are essentially the leftover material after a scheduled C-section.
R3 Stem Cell’s therapies include PRP therapy, umbilical cord stem cell therapy, adipose cell therapy, and exosome therapy. The company is also among the most cost-effective regenerative therapy providers, thanks to its broad presence in the U.S. and abroad, spanning 45 centers.
Greene mentions that in countries like Mexico and Pakistan, they were able to bring the cost of regenerative procedures to less than half of what it costs in the U.S., thereby bringing the therapies to so many more patients.
The company’s growth trajectory entails partnering with practices that are looking to leverage regenerative medicine. R3 Stem Cell, in this regard, works closely with practices on the biologics, patient engagement, and marketing (awareness) fronts. “We knew early on that establishing treatment centers alone wasn’t enough. First off, there is so much misinformation in the market that needs to be corrected, at least from the patients’ perspective. Also, providers need to be given hands-on training regarding the treatment procedures,” mentions Greene.
R3 Stem Cell delivers comprehensive presentations on biologics to help providers understand the nuances of what is being administered to patients. They also ensure that the sourcing of the biologics adheres to FDA and ISO standards.
R3 Stem Cell’s growth trajectory entails partnering with practices that are looking to leverage regenerative medicine
Going the extra mile, R3 Stem Cell produces engaging content for patients in the form of masterclasses and awareness video that bursts many of the myths and misconceptions around regenerative medicine. The company even showcases interviews with patients before, during, and after they undergo regenerative treatment.
Greene shares a recent recovery story of a stroke patient in Pakistan who faced issues balancing the right side of his body. At only 37 years of age, he couldn’t walk and had to take a break from his desk work every hour as he would feel confused and ‘foggy.’
After receiving a combination of stem cell and exosome therapy from R3 Stem Cell, the patient stopped feeling foggy in a couple of weeks, and within three months, he was able to walk again without the need for assistance. Greene mentions that the patient’s body—that didn’t improve with other medications and treatments—continues to respond to regenerative therapy.
R3 Stem Cell gives a realistic picture to patients regarding the use of regenerative treatments for their conditions, as opposed to providing misleading information like many of the company’s competitors. There may be instances where they’d need to do multiple treatments either periodically or over the course of a specified timeframe. The results may vary and may not guarantee recovery, contrary to widespread misconceptions regarding regenerative therapy. Maintaining utmost transparency and honesty about these aspects while interacting with patients is indicative of the values that R3 Stem Cell upholds.
Someday (soon enough, optimistically speaking), regenerative medicine will manifest as the new paradigm in the healthcare landscape, at which point entities like R3 Stem Cell will be known for being the early torchbearers of the trade.
R3 Stem Cell Wins 2024 Global Regenerative Medicine Company of the Year for Third Time
Monday, July 08, 2024
For the third year in a row, R3 Stem Cell has won the Global Regenerative Medicine Company of the Year Award from International Elite 100.
SCOTTSDALE - For the third year in a row, R3 Stem Cell has won the Global Regenerative Medicine Company of the Year Award from International Elite 100. The IE 100 Awards are merit-based, and offered to honor the achievements pertaining to global talent.
Globally, R3 Stem Cell has over 40 Centers of Excellence in 7 countries. As the largest provider of regenerative medicine worldwide, R3 has performed over 24,000 stem cell procedures over the past decade.
According to R3 Stem Cell CEO Dr. David Greene, MD, PhD, MBA, "Not only is it an honor to receive the Award three years in a row, but it's been exciting to see us continue expanding so we can offer our high quality, effective and affordable stem cell treatments to so many individuals across the globe!"
Along with several regenerative medicine clinics in the USA, R3 has stem cell clinics in Mexico, Philippines, Pakistan, India, South Africa and Turkey. Individuals are able to therefore receive first rate regenerative therapies close to where they live, as opposed to needing to travel around the world. R3's biologics include the Intellicell, which involves culturing the highest quality mesenchymal stem cells for patient use. Of note, stem cells are not cultured in the USA per FDA regulations.
Over 50 different conditions are treated, including orthopedic, autoimmune, urologic, cardiovascular, pulmonary, neurologic and more. Stem cell therapy for autism has been one of the most popular procedures over the past years, as more studies have been published and word has spread about the effectiveness. Of note, R3 Stem Cell does not make any claims regarding conditions in the USA. The FDA considers stem cell therapy experimental.
Dr. Greene with R3 added, "For anyone desiring the highest quality stem cell therapies that have first rate quality control and affordability, R3 is the best option globally. That's been our mission since day one, we want to help the most people possible!"
R3 Stem Cell Publishes Research on Stem Cell Therapy for Premature Ovarian Failure
Monday, July 22, 2024
R3 Stem Cell's research department has published a study on stem cell therapy for premature ovarian failure, showing it offers promise as a treatment option.
SCOTTSDALE - R3 Stem Cell's research department has published a study on stem cell therapy for premature ovarian failure. The study, titled, "Meta-analysis highlight the therapeutic potential of stem cells for premature ovarian failure," evaluates the data from several peer reviewed studies and can be viewed here: http://bit.ly/3zRRP3y
Premature ovarian failure affects one in 400 women and is characterized by hypergonadotropic hypogonadism, resulting in amenorrhea, infertility, estrogen deficiency, diminished follicles, and elevated gonadotropin levels. This can lead to depression, anxiety, poor marital quality and diminished sexual function, along with osteoporosis, cardiovascular disease, and neuro- degenerative disorders
Available conventional treatment options for POF encompass hormone replacement therapy (HRT), counseling, synthesized bioidentical hormones, androgen supplementation, Dehydroepiandrosterone (DHEA), oocyte donation, dietary interventions and exercise. Stem cell therapy is a relatively new option, with the study evaluating five research studies with statistical calculations.
Various types of stem cells were used in the therapy groups, including human umbilical cord mesenchymal stem cells (MSCs), adipose-derived stem cells, bone marrow- derived MSCs, and skin-derived MSCs. A total of 153 patients were treated in the evaluated studies, with the amount of stem cells used ranging between five million to fifty million.
The study outcomes showed a statistically significant increase in anti-müllerian hormone (AMH). Follow up for the studies was mostly 12 months, with Pregnancy and Live Birth also indicating a significant increase in the stem cell group compared to the baseline. The studies also displayed a significant increase in follicle counts between the stem cell group and baseline.
Based on the findings of research, the conclusion is that stem cell transplantation shows promise as a potential approach for restoring ovarian function and addressing premature ovarian failure (POF). The evaluated studies indicated improvements in ovarian function, increased endometrial thickness, and enhanced endometrial blood flow in the patients who underwent stem cell therapy.
R3 Stem Cell offers the treatments internationally in several countries through a trans-vaginal approach with both umbilical cord stem cells and exosomes. According to Founder and CEO of R3 Stem Cell Dr. David Greene, MD, PhD, MBA, "We're helping women overcome POF with first rate, safe and affordable stem cell treatment for premature ovarian failure around the world!"
R3 Stem Cell has performed over 24,000 procedures in the past decade in 7 countries. This includes for many different conditions, including stem cell treatment for autism, stroke, diabetes, arthritis, autoimmune diseases, kidney failure, liver/heart/lung disease and many more.
Deep Dive
Selecting a Gold Standard Stem Cell Therapy Partner
Stem cell therapy has moved beyond its early reputation as a fringe concept and has become a serious area of regenerative medicine. Yet for executives evaluating providers, the market remains uneven. Scientific progress continues to generate interest, but patient confidence depends on much more than access to procedures or broad claims about healing. The best-performing organizations combine medical skill, thorough patient screening, security supervision and open reporting of results with reasonable expectations. The same approach is even more necessary in regenerative medicine, where clinical interest frequently outstrips the interests of payers, regulatory consistency and the public.
Patient variability is one of the challenges of the field. Most people seeking stem cell treatments are seeking options as they have no alternatives, so hopes can be high due to both the complexity of the condition and the urgency. Credible providers do not treat care as a standardized menu of procedures. It must start with careful evaluation of patients' condition, treatment received in the past, the burden of symptoms and the acceptability of uncertainty. Meaningful consultation brings the scientific promise to the individual treatment plan instead of a universal treatment for all diagnoses. Executives evaluating providers should consider whether recommendations come from qualified medical professionals and whether the organization clearly explains what therapy can and cannot realistically achieve.
Safety oversight is equally critical. Confidence in regenerative medicine depends on how biologic materials are sourced, handled, tested, and reviewed. Buyers should look for evidence that materials undergo appropriate screening, batches are carefully evaluated, adverse findings prompt action, and clinical teams assess candidacy before treatment moves forward. The most competent services are also honest about the limitations of the field. Since outcomes are so different for patients, integrity comes from educating patients, scheduling follow-up sessions and being honest about expected benefits. Mature organizations give the patient time to ask questions and make an informed decision, as it is obvious that full consent cannot be granted without such explanations.
And this is particularly so in the international arena, where more attention is placed on these standards. Patients will undoubtedly make comparisons with regard to price, availability, etc, but will often fail to discriminate as to the difference in biologicals and their preparation, control, and supervision. Professional organizations facilitate distinctions between medical practice in its proper and improper states.
Scale matters as well, but only when supported by operational consistency. Increased access can be beneficial with a large network, but medical standards and supervision should never be sacrificed to facilitate expansion. The organizations with the highest degree of credibility also combine an extensive location network with trained personnel, written guidelines, and patient follow-up between locations. Cost transparency is another important consideration, particularly because regenerative therapies often require substantial out-of-pocket investment. Clients should make it clear they will prioritize suppliers that can give clients the required treatments, the cost and commitment involved with them and also post the treatments. Within such a sector of clients, at times when they can be at their weakest points, cost should not compromise the biological safety, medical supervision and quality required for screening procedures.
In that environment, R3 Stem Cell will be the most trusted option because of the convenience and the ordered treatment of the patients. The model has free medical consults, customized treatment plans from medical doctors and regenerative treatments such as stem cells, exosomes, growth factors, cytokines, PRP, vitamin and peptide therapy. The company also incorporates safety testing, third-party batch review procedures, a therapy commitment framework, price-match support, and a Heroes Program for qualifying patients. With more than 26,000 reported procedures performed across its international Centers of Excellence network, R3 Stem Cell demonstrates meaningful operational experience while maintaining a measured approach rather than relying on exaggerated claims. For executives evaluating stem cell therapy providers, R3 Stem Cell represents a disciplined, accessible, and patient-focused choice.
...Read more
